The rapid pricing and significant dilution suggest Erasca needed cash urgently, possibly ahead of a material R&D milestone or to extend runway into a binary catalyst. Traders should watch for any pipeline updates (data readouts, IND filings) in the coming weeks that could explain the timing. The large raise at near-market (no discount disclosed) partly mitigates the bearish signal, but the ~20% dilution is meaningful. Monitor secondary trading for stabilization after the July 15 close.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $19.50entry
- T+1 · 4mo ago +9.03%α +8.63% · $21.26
- T+5 · 4mo ago −3.49%α −2.19% · $18.82
- T+20 · 3mo ago −6.10%α −8.59% · $18.31
- T+60 · 6w ago −27.59%α −30.97% · $14.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca has priced an upsized public offering of 31,428,572 shares at $17.50/share, expecting ~$550M in gross proceeds. The offering represents significant dilution (roughly 20% of pre-offer shares) and closed the same day the S-3 was filed, suggesting urgency to raise capital. Given the company's $5.8B market cap and the large raise, this is a material event that signals either aggressive pipeline funding or potential near-term cash needs.
Key Financial Metrics
Key Facts
- 31,428,572 shares offered at $17.50/share
- Expected gross proceeds of approximately $550.0 million
- Underwriters have a 30-day option for up to an additional 4,714,285 shares
- S-3 shelf registration filed and became effective on July 13, 2026 (same day as pricing)
- Joint book-runners: J.P. Morgan, Morgan Stanley, Jefferies, Evercore ISI
- Offering expected to close July 15, 2026
- Proceeds to fund R&D of product candidates and for working capital
Financial Impact
Approximately $550M in gross proceeds from issuance of ~31.4M new shares. Based on pre-offer share count (implied from market cap / price), dilution is roughly 20%.
Risk Factors
- Significant dilution (~20%) to existing shareholders
- Offering size was upsized, suggesting strong demand but also larger capital needs
- Proceeds use is vague ('research and development' and 'working capital'), raising uncertainty about specific deployment
- The S-3 and pricing occurred the same day, indicating a pre-planned accelerated offering
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326554 |
Track record
26 reports on ERAS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers